Skip Navigation

European Heart Journal 2004 25(1):1-2; doi:10.1016/j.ehj.2003.08.006
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Duprez, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duprez, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

HOPE brings hope for the use of the ankle-brachial index as cardiovascular risk marker

Daniel Duprez*

Cardiovascular Division, University of Minneapolis, 420 Delaware Street SE, Minneapolis, MN 55455, USA

* Correspondence to: Tel: +1 612-624-4948; Fax: +1 612-626-4411
E-mail address: dupree007@umn.edu

Received 19 August 2003; accepted 28 August 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/j.ehj.2003.10.033for the article to which this editorial refers

In this issue Ostergren et al.1studied the prognostic importance of the ankle-brachial index (ABI) and the risk reduction by the ACE-inhibitor, ramipril of major cardiovascular events in patients with clinical as well assubclinical peripheral arterial disease.

The authors used a very . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease
J. Östergren, P. Sleight, G. Dagenais, K. Danisa, J. Bosch, Yi Qilong, S. Yusuf, and for the HOPE study investigators
EHJ 2004 25: 17-24. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur J OrthodHome page
V. S. Lucas, A. Kyriazidou, M. Gelbier, and G. J. Roberts
Bacteraemia following debanding and gold chain adjustment
Eur J Orthod, April 1, 2007; 29(2): 161 - 165.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
G. G L Biondi-Zoccai, M. Lotrionte, A. Abbate, L. Testa, E. Remigi, F. Burzotta, M. Valgimigli, E. Romagnoli, F. Crea, and P. Agostoni
Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study
BMJ, January 28, 2006; 332(7535): 202 - 209.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
I. Paetsch, D. Foll, A. Kaluza, R. Luechinger, M. Stuber, A. Bornstedt, A. Wahl, E. Fleck, and E. Nagel
Magnetic resonance stress tagging in ischemic heart disease
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2708 - H2714.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J., April 2, 2005; 26(8): 804 - 847.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
T. Arimura, A. Helbling-Leclerc, C. Massart, S. Varnous, F. Niel, E. Lacene, Y. Fromes, M. Toussaint, A.-M. Mura, D. I. Keller, et al.
Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies
Hum. Mol. Genet., January 1, 2005; 14(1): 155 - 169.
[Abstract] [Full Text] [PDF]